CHUKYOIYAKUHIN CO.,LTD.
4558・Standard Market・Pharmaceuticals
Retail Division (Health Care Business)
Core business responsible for the placement and retail sales of products to households through sales staff
| Period | Current | Previous | Change |
|---|---|---|---|
| Net sales (full year, FY2026 (ending March 2026)) | ¥3,898 million | ¥3,836 million | ↑ |
| Segment profit (full year, FY2026 (ending March 2026)) | ¥74 million | ¥31 million | ↑ |
| Segment assets (full year, FY2026 (ending March 2026)) | ¥1,736 million | ¥1,793 million | ↓ |
| Haichi sales revenue (full year, FY2026 (ending March 2026)) | ¥902 million | ¥938 million | ↓ |
| Share of net sales (full year, FY2026 (ending March 2026)) | 59.3% | 60.8% | ↓ |
Business Details
The Retail Division, which forms the core of the Household Pharmaceuticals Sales Business, has sales staff visit households directly to conduct Haichi sales and retail sales of Stocked Home Medicine (Haichi-yaku), Health Foods, Drinks, Medical Products, sundries, and daily living distribution products. In FY2026 (ending March 2026), net sales were ¥3,898 million, accounting for 59.3% of consolidated net sales, making it the largest segment. The company leverages its face-to-face human network, known as the "Fureai" business, as a source of competitive advantage, and is working to improve profitability through the introduction of new and renewed products and the promotion of consignment sales.
Recent Overview
Both net sales and segment profit improved, led by daily living distribution products
In FY2026 (ending March 2026), Retail Division net sales were ¥3,898 million (up 1.6% year on year), and segment profit was ¥74 million (a significant improvement from ¥31 million in the prior period). The introduction of new and renewed products, along with the optimization of selling prices, successfully improved profitability. By item, Daily Living Distribution & Others showed strong growth at ¥2,271 million (up 13.2% year on year), while Stocked Home Medicine (Haichi-yaku) fell to ¥557 million (down 3.7% year on year) and Drinks fell to ¥622 million (down 9.4% year on year), with the Haichi products category overall continuing to decline by 1.9%. The Household Pharmaceuticals Sales Business as a whole (Retail plus Wholesale) recorded an impairment loss of ¥24 million.
Key Products
Growth Drivers
- Optimization of selling prices and improvement of profit margins through the introduction of new and renewed products
- Establishment of a stable revenue base and acquisition of new customers by promoting consignment sales of Haichi products and other items
- Productivity improvement through the formulation and execution of category-specific action plans
- Strengthening organizational capabilities through hierarchical sales staff training, reinforcement of the promoter system, and training for female sales staff
- Diversification of the sales mix through the expansion of Daily Living Distribution & Others products (up 13.2% year on year)
- Development of new customers through the flexible establishment of satellite offices
Risks
- Profit pressure from the worsening labor shortage and rising wage costs (salaries and allowances of ¥1,561 million, the largest SG&A item)
- Continued increases in procurement and logistics costs
- Decline in consumer purchasing appetite due to inflation risk
- Structural decline in Haichi sales revenue (¥902 million in FY2026 (ending March 2026), down 3.8% year on year)
- Impairment risk on fixed assets (an impairment loss of ¥24 million was recorded in the Household Pharmaceuticals Sales Business in FY2026 (ending March 2026))
- Potential impact on net sales from an increase in holidays, given the labor-intensive nature of the business
Last updated: June 24, 2026